Company intelligence / Profile preview

BforCure

Montreuil, France

Ownership: Private
Employees: ~35
Development stage: Other

Overview

BforCure has commercialized the Chronos device and associated PCR-based assays for rapid microorganism detection, including CE-IVD marked COVID-19 and combination COVID/influenza tests; over 30 devices and 20,000 tests sold, generating over €4M turnover[2][3].

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: DevicePCR-based diagnosticsDigital PCRReal-time PCRBioinformatics
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on BforCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BforCure.

Explore the full profile